Asset Details

MbrlCatalogueTitleDetail

Do you wish to reserve the book?

Darolutamide and Survival in Metastatic, Hormone-Sensitive Prostate Cancer

by Hussain, Maha , Thiele, Silke , Tammela, Teuvo L.J , Montesa-Pino, Álvaro , Kuss, Iris , Parnis, Francis , Cruz, Felipe , Crawford, E. David , Tombal, Bertrand , Méndez-Vidal, María J , Fu, Cheng , Alekseev, Boris , Joensuu, Heikki , Utriainen, Tapio , Suzuki, Hiroyoshi , Fizazi, Karim , Park, Chandler H , Saad, Fred , Smith, Matthew R , Ye, Dingwei , Kopyltsov, Evgeny , Sternberg, Cora N , Maughan, Benjamin L , Uemura, Motohide , Li, Rui

in Aged / Aged, 80 and over / Androgen Antagonists - therapeutic use / Androgen Receptor Antagonists - adverse effects / Androgen Receptor Antagonists - therapeutic use / Androgens / Antineoplastic Agents - adverse effects / Antineoplastic Agents - therapeutic use / Cancer therapies / Castration / Docetaxel - adverse effects / Docetaxel - therapeutic use / Drug dosages / Drug Therapy, Combination / Genitourinary Cancer / Hematology / Hormones / Humans / Kaplan-Meier Estimate / Magnetic resonance imaging / Male / Metastases / Metastasis / Middle Aged / Narcotics / Neoplasm Metastasis - drug therapy / Neutropenia / Neutropenia - chemically induced / Oncology / Pain / Patients / Placebos / Proportional Hazards Models / Prostate cancer / Prostate Disease / Prostate Disease General / Prostatic Neoplasms - drug therapy / Prostatic Neoplasms - mortality / Prostatic Neoplasms - pathology / Prostatic Neoplasms, Castration-Resistant / Pyrazoles - adverse effects / Pyrazoles - therapeutic use / Questionnaires / Statistical analysis / Survival / Treatments in Oncology / Urology

2022

Yes Please

Hey, we have placed the reservation for you!

By the way, why not check out events that you can attend while you pick your title.

Oops! Something went wrong.

Looks like we were not able to place the reservation. Kindly try again later.

Are you sure you want to remove the book from the shelf?

Darolutamide and Survival in Metastatic, Hormone-Sensitive Prostate Cancer

2022

Confirm

Do you wish to request the book?

Darolutamide and Survival in Metastatic, Hormone-Sensitive Prostate Cancer

2022

Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy

How would you like to get it?

Submit

We have requested the book for you!

Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.

Oops! Something went wrong.

Looks like we were not able to place your request. Kindly try again later.

Journal Article

Darolutamide and Survival in Metastatic, Hormone-Sensitive Prostate Cancer

Hussain, Maha,

Thiele, Silke,

Tammela, Teuvo L.J,

Montesa-Pino, Álvaro,

Kuss, Iris,

Parnis, Francis,

Cruz, Felipe,

Crawford, E. David,

Tombal, Bertrand,

Méndez-Vidal, María J,

Fu, Cheng,

Alekseev, Boris,

Joensuu, Heikki,

Utriainen, Tapio,

Suzuki, Hiroyoshi,

Fizazi, Karim,

Park, Chandler H,

Saad, Fred,

Smith, Matthew R,

Ye, Dingwei,

Kopyltsov, Evgeny,

Sternberg, Cora N,

Maughan, Benjamin L,

Uemura, Motohide,

Li, Rui

2022

Overview

Standard therapy for metastatic, hormone-sensitive prostate cancer is androgen-deprivation therapy, usually with docetaxel. A large, multinational, phase 3 trial assessed the addition of the androgen-receptor blocker darolutamide to standard therapy. At 4 years, survival was higher with darolutamide than with placebo (62.7% vs. 50.4%), with no major differences in the frequency of adverse events.

Share this book

Add to My Shelf

Publisher

Massachusetts Medical Society

Subject

Aged

/ Aged, 80 and over

/ Androgen Antagonists - therapeutic use

/ Androgen Receptor Antagonists - adverse effects

/ Androgen Receptor Antagonists - therapeutic use

/ Androgens

/ Antineoplastic Agents - adverse effects